DALIAN, China -- Sinovac Biotech has begun manufacturing a coronavirus vaccine candidate on a pilot basis, as China shifts toward the mass production stage in the global immunization race.
Production has started at a new plant in Beijing with an annual capacity of roughly 300 million doses. Sinovac has agreed to supply 40 million doses to Bio Farma, an Indonesian state-owned company, between November and March. Sinovac started building the factory in late March and finished the project in July.
